Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sugen (SUGN) -- Ignore unavailable to you. Want to Upgrade?

To: Larry L who wrote (161)	5/4/1998 11:00:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 550

Larry, You are bit off in statement. First, I was unhappy with SUGN IR (not because they do not hype/advertise stock) because they didn't answer on my e-mail for some time. I needed additional information (for sound and objective decision) to complete my research on SUGN cancer programs. After discussion with Mr. K. Kwok and further DD, I found SUGN as one of advanced and very promising player in anti-angiogenesis and cancer field generally, with more than 10 targets. So, I silently accumulated stock and now am happy camper (for long, long haul). >>How can Intermed (sp), a company 2 years behind Sugen with basically the same idea, go up 367% in one day while Sugen sits by and does nothing? << Entremed and SUGN do not have closely some idea, even they have some target: angiogenesis. How Endostatin/Angiostatin work nobody knows, still mostly speculation regardless mice results. SUGN VEGF target is confirmed (?) with GNE mAb PI trial data and their own PI results. SUGN do not needs WS hype (if it is for real, still I will not object if price rise ( I hope that will not be out of control like today for ENMD/BLSI). I hope that I can continue adding to my position as my finance allowed. Regards, Miljenko